Found 23 resultsAuthor [ Title] Type Year
Filters: Author is Hill, H [Clear All Filters]
Assessment of Safety in Newborns of Mothers Participating in Clinical Trials of Vaccines Administered During Pregnancy. Clin Infect Dis, 59 Suppl 7, S415-427. presented at the 12/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25425720. (2014).
Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response. In ID Week 2014. presented at the 08/10/2014, Philadelphia, PA. Retrieved from http://www.idweek.org/post-meeting-tools/. (2014).
Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children. Pediatr Infect Dis J, 33, 865-871. presented at the 08/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25222307. (2014).
Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults. Vaccine, 29, 5666-5674. presented at the 08/2011. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21699951. (2011).
Determination of the 50% Human Infectious Dose for Norwalk Virus. J Infect Dis, 209, 1016-1022. presented at the 04/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24253285. (2014).
Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes. J Infect Dis, 206, 1069-1077. presented at the 10/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22891287. (2012).
Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine, 37(37), 5535-5543. presented at the 2019 09 03. doi:10.1016/j.vaccine.2019.04.066. (2019).
Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults. J Infec Dis, 197, 667-675. presented at the 03/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18260764. (2008).
Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming with an Antigenic Variant. J Infec Dis, 198, 635-641. presented at the 09/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18694338. (2008).
Immunogenicity and Safety of Four Different Dosing Regimens of Anthrax Vaccine Adsorbed for Post-Exposure Prophylaxis for Anthrax in Adults. Vaccine, 32, 6284-6293. presented at the 09/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25239484. (2014).
Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. J Infect Dis, 206, 811-820. presented at the 09/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22782949. (2012).
Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial. JAMA, 312, 1420-1428. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25291578. (2014).
Phase 2 Assessment of the Safety and Immunogenicity of Two Inactivated Pandemic Monovalent H1N1 Vaccines in Adults as a Component of the U.S. Pandemic Preparedness Plan in 2009. Vaccine, 13, 4240-4248. presented at the 06/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=22537984. (2012).
Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5×10(8) TCID 50) of Modified Vaccinia Ankara Compared to a Standard Dose (1×10(8) TCID50) in Healthy Vaccinia-Naïve Individuals. Vaccine, 32, 2732-2739. presented at the 05/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24607004. (2014).
Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. Vaccine, 33, 163-173. presented at the 01/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25444805. (2015).
PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4 T cell transcriptomal molecular signatures. Mucosal Immunol, 11(2), 486-495. presented at the 2018 03. doi:10.1038/mi.2017.67. (2018).
Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure. Clin Vaccine Immunol, 16, 558-566. presented at the 04/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19225073. (2009).
Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. J Infect Dis, 206, 828-837. presented at the 09/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=22802432. (2012).
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis, 212, 525-530. presented at the 08/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25712967. (2015).
Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults. Vaccine, 27, 5091-5095. presented at the 08/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=19577636. (2009).
Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given Without or With Aluminum Hydroxide to Healthy Adults: Results of a Phase I-II Randomized Clinical Trial. J Infec Dis, 198, 1309-1316. presented at the 11/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18808338. (2009).
Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults. Vaccine, 28, 6367-6373. presented at the 08/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20619382. (2010).
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial. J Infect Dis, 207, 1888-1897. presented at the 06/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23482644. (2013).